Differences in Outcomes between Early and Late Diagnosis of Cystic Fibrosis in the Newborn Screening Era

Journal of Pediatrics

Volumn 181, Issue , 2017, Pages 137-145.e1

  Coffey, Michael J ^a   Whitaker, Viola ^a   Gentin, Natalie ^a,b   Junek, Rosie ^c   Shalhoub, Carolyn ^b   Nightingale, Scott ^d,e   Hilton, Jodi ^e,f   Wiley, Veronica ^c,g   Wilcken, Bridget ^c,g   Gaskin, Kevin J ^c,g   Ooi, Chee Y ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

^e JOHN HUNTER CHILDREN S HOSPITAL   (Australia)

^f UNIVERSITY OF NEWCASTLE   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Australia; cystic fibrosis transmembrane conductance regulator; growth; lung function

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BACTERIAL COLONIZATION; BODY MASS; BODY WEIGHT; CHILD; CHILD HOSPITALIZATION; CLINICAL ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; CYSTIC FIBROSIS; DELAYED DIAGNOSIS; EARLY DIAGNOSIS; EVALUATION STUDY; EXPIRATORY RESERVE VOLUME; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HUMAN; INCIDENCE; LIVE BIRTH; LUNG FUNCTION; MALE; MECONIUM ILEUS; MEDICAL RECORD REVIEW; NEW SOUTH WALES; NEWBORN SCREENING; PANCREAS FUNCTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; SCHOOL CHILD; SWEAT TEST; YOUNG ADULT; ADVERSE EFFECTS; AGE; COMPARATIVE STUDY; DISEASE COURSE; FACTUAL DATABASE; HOSPITALIZATION; LUNG FUNCTION TEST; MORTALITY; NEWBORN; OUTCOME ASSESSMENT; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE;

AGE FACTORS; CYSTIC FIBROSIS; DATABASES, FACTUAL; DELAYED DIAGNOSIS; DISEASE PROGRESSION; FEMALE; HOSPITALIZATION; HUMANS; INFANT, NEWBORN; MALE; NEONATAL SCREENING; NEW SOUTH WALES; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SURVIVAL RATE;

EID: 85006314493     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2016.10.045     Document Type: Article

References (60)

1. 1 Massie, R.J., Olsen, M., Glazner, J., Robertson, C.F., Francis, I., Newborn screening for cystic fibrosis in Victoria: 10 years’ experience (1989-1998). Med J Aust 172 (2000), 584–587.
2. 2 Parad, R.B., Comeau, A.M., Newborn screening for cystic fibrosis. Pediatr Ann 32 (2003), 528–535.
3. 3 Comeau, A.M., Parad, R.B., Dorkin, H.L., Dovey, M., Gerstle, R., Haver, K., et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics 113 (2004), 1573–1581.
4. 4 Sontag, M.K., Hammond, K.B., Zielenski, J., Wagener, J.S., Accurso, F.J., Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. J Pediatr 147 (2005), S83–8.
5. 5 Riordan, J.R., Rommens, J.M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science (New York, NY) 245 (1989), 1066–1073.
6. 6 Massie, R.J., Curnow, L., Glazner, J., Armstrong, D.S., Francis, I., Lessons learned from 20 years of newborn screening for cystic fibrosis. Med J Aust 196 (2012), 67–70.
7. 7 Rock, M.J., Hoffman, G., Laessig, R.H., Kopish, G.J., Litsheim, T.J., Farrell, P.M., Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing. J Pediatr 147 (2005), S73–7.
8. 8 Gonska, T., Ratjen, F., Newborn screening for cystic fibrosis. Expert Rev Respir Med 9 (2015), 619–631.
9. 9 Wilcken, B., Brown, A.R., Urwin, R., Brown, D.A., Cystic fibrosis screening by dried blood spot trypsin assay: results in 75,000 newborn infants. J Pediatr 102 (1983), 383–387.
10. 10 Wilcken, B., Wiley, V., Sherry, G., Bayliss, U., Neonatal screening for cystic fibrosis: a comparison of two strategies for case detection in 1.2 million babies. J Pediatr 127 (1995), 965–970.
11. 11 Southern, K.W., Merelle, M.M., Dankert-Roelse, J.E., Nagelkerke, A.D., Newborn screening for cystic fibrosis. Cochrane Database Syst Rev(1), 2009 CD001402.
12. 12 Farrell, P.M., Kosorok, M.R., Rock, M.J., Laxova, A., Zeng, L., Lai, H.C., et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Pediatrics 107 (2001), 1–13.
13. 13 Farrell, P.M., Li, Z., Kosorok, M.R., Laxova, A., Green, C.G., Collins, J., et al. Bronchopulmonary disease in children with cystic fibrosis after early or delayed diagnosis. Am J Respir Crit Care Med 168 (2003), 1100–1108.
14. 14 Wald, N.J., Morris, J.K., Neonatal screening for cystic fibrosis. BMJ 316 (1998), 404–405.
15. 15 Waters, D.L., Wilcken, B., Irwing, L., Van Asperen, P., Mellis, C., Simpson, J.M., et al. Clinical outcomes of newborn screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed 80 (1999), F1–7.
16. 16 Merelle, M.E., Nagelkerke, A.F., Lees, C.M., Dezateux, C., Newborn screening for cystic fibrosis. Cochrane Database Syst Rev(3), 2001 CD001402.
17. 17 Grosse, S.D., Boyle, C.A., Botkin, J.R., Comeau, A.M., Kharrazi, M., Rosenfeld, M., et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. Morbid Mortal Recomm Rep 53 (2004), 1–36.
18. 18 McKay, K.O., Waters, D.L., Gaskin, K.J., The influence of newborn screening for cystic fibrosis on pulmonary outcomes in New South Wales. J Pediatr 147 (2005), S47–50.
19. 19 Rosenthal, M., Newborn screening for cystic fibrosis: the motion against–voices in the wilderness. Paediatr Respir Rev 9 (2008), 295–300.
20. 20 Farrell, P.M., Rosenstein, B.J., White, T.B., Accurso, F.J., Castellani, C., Cutting, G.R., et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 153 (2008), S4–14.
21. 21 Dijk, F.N., McKay, K., Barzi, F., Gaskin, K.J., Fitzgerald, D.A., Improved survival in cystic fibrosis patients diagnosed by newborn screening compared to a historical cohort from the same centre. Arch Dis Child 96 (2011), 1118–1123.
22. 22 Massie, R.J., Wilcken, B., Van Asperen, P., Dorney, S., Gruca, M., Wiley, V., et al. Pancreatic function and extended mutation analysis in DeltaF508 heterozygous infants with an elevated immunoreactive trypsinogen but normal sweat electrolyte levels. J Pediatr 137 (2000), 214–220.
23. 23 Borowitz, D., Parad, R.B., Sharp, J.K., Sabadosa, K.A., Robinson, K.A., Rock, M.J., et al. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. J Pediatr 155 (2009), S106–16.
24. 24 Mayell, S., Management of equivocal diagnosis, the European consensus project. European Cystic Fibrosis Conference 2014, 2014 Gothenburg, Sweden; June 13.
25. 25 Waite, R.D., Wareham, D.W., Gardiner, S., Whiley, R.A., A simple, semiselective medium for anaerobic isolation of anginosus group streptococci from patients with chronic lung disease. J Clin Microbiol 50 (2012), 1430–1432.
26. 26 Sosnay, P.R., Siklosi, K.R., Van Goor, F., Kaniecki, K., Yu, H., Sharma, N., et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 45 (2013), 1160–1167.
27. 27 Cystic Fibrosis Mutation Database (CFTR1). www.genet.sickkids.on.ca/, 2011 Accessed January 12, 2016.
28. 28 Pressler, T., Bohmova, C., Conway, S., Dumcius, S., Hjelte, L., Hoiby, N., et al. Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. J Cyst Fibros 10:Suppl 2 (2011), S75–8.
29. 29 Kloosterboer, M., Hoffman, G., Rock, M., Gershan, W., Laxova, A., Li, Z., et al. Clarification of laboratory and clinical variables that influence cysticfibrosis newborn screening with initial analysis of immunoreactive trypsinogen. Pediatrics 123 (2009), e338–46.
30. 30 Sanders, D.B., Lai, H.J., Rock, M.J., Farrell, P.M., Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies. J Cyst Fibros 11 (2012), 150–153.
31. 31 Munck, A., Mayell, S.J., Winters, V., Shawcross, A., Derichs, N., Parad, R., et al. Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): a new designation and management recommendations for infants with an inconclusive diagnosis following newborn screening. J Cyst Fibros 14 (2015), 706–713.
32. 32 Ramsey, B.W., Davies, J., McElvaney, N.G., Tullis, E., Bell, S.C., Drevinek, P., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365 (2011), 1663–1672.
33. 33 Boyle, M.P., Bell, S.C., Konstan, M.W., McColley, S.A., Rowe, S.M., Rietschel, E., et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2 (2014), 527–538.
34. 34 Imrie, J.R., Fagan, D.G., Sturgess, J.M., Quantitative evaluation of the development of the exocrine pancreas in cystic fibrosis and control infants. Am J Pathol 95 (1979), 697–707.
35. 35 Couper, R.T., Corey, M., Durie, P.R., Forstner, G.G., Moore, D.J., Longitudinal evaluation of serum trypsinogen measurement in pancreatic-insufficient and pancreatic-sufficient patients with cystic fibrosis. J Pediatr 127 (1995), 408–413.
36. 36 McKay, K., Wilcken, B., Newborn screening for cystic fibrosis offers an advantage over symptomatic diagnosis for the long term benefit of patients: the motion for. Paediatr Respir Rev 9 (2008), 290–294.
37. 37 Wilcken, B., Chalmers, G., Reduced morbidity in patients with cystic fibrosis detected by neonatal screening. Lancet (London, England) 2 (1985), 1319–1321.
38. 38 Dankert-Roelse, J.E., te Meerman, G.J., Martijn, A., ten Kate, L.P., Knol, K., Survival and clinical outcome in patients with cystic fibrosis, with or without neonatal screening. J Pediatr 114 (1989), 362–367.
39. 39 Siret, D., Bretaudeau, G., Branger, B., Dabadie, A., Dagorne, M., David, V., et al. Comparing the clinical evolution of cystic fibrosis screened neonatally to that of cystic fibrosis diagnosed from clinical symptoms: a 10-year retrospective study in a French region (Brittany). Pediatr Pulmonol 35 (2003), 342–349.
40. 40 Accurso, F.J., Sontag, M.K., Wagener, J.S., Complications associated with symptomatic diagnosis in infants with cystic fibrosis. J Pediatr 147 (2005), S37–41.
41. 41 Sims, E.J., McCormick, J., Mehta, G., Mehta, A., Newborn screening for cystic fibrosis is associated with reduced treatment intensity. J Pediatr 147 (2005), 306–311.
42. 42 Farrell, P.M., Kosorok, M.R., Laxova, A., Shen, G., Koscik, R.E., Bruns, W.T., et al. Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. N Engl J Med 337 (1997), 963–969.
43. 43 Dankert-Roelse, J.E., te Meerman, G.J., Long term prognosis of patients with cystic fibrosis in relation to early detection by neonatal screening and treatment in a cystic fibrosis centre. Thorax 50 (1995), 712–718.
44. 44 Mastella, G., Zanolla, L., Castellani, C., Altieri, S., Furnari, M., Giglio, L., et al. Neonatal screening for cystic fibrosis: long-term clinical balance. Pancreatology 1 (2001), 531–537.
45. 45 Kosorok, M.R., Zeng, L., West, S.E., Rock, M.J., Splaingard, M.L., Laxova, A., et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 32 (2001), 277–287.
46. 46 Li, Z., Kosorok, M.R., Farrell, P.M., Laxova, A., West, S.E., Green, C.G., et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 293 (2005), 581–588.
47. 47 Schaedel, C., de Monestrol, I., Hjelte, L., Johannesson, M., Kornfalt, R., Lindblad, A., et al. Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol 33 (2002), 483–491.
48. 48 Sanders, D.B., Li, Z., Laxova, A., Rock, M.J., Levy, H., Collins, J., et al. Risk factors for the progression of cystic fibrosis lung disease throughout childhood. Ann Am Thorac Soc 11 (2014), 63–72.
49. 49 Mayer-Hamblett, N., Kronmal, R.A., Gibson, R.L., Rosenfeld, M., Retsch-Bogart, G., Treggiari, M.M., et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol 47 (2012), 125–134.
50. 50 Treggiari, M.M., Retsch-Bogart, G., Mayer-Hamblett, N., Khan, U., Kulich, M., Kronmal, R., et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 165 (2011), 847–856.
51. 51 Baumann, U., Stocklossa, C., Greiner, W., von der Schulenburg, J.M., von der Hardt, H., Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros 2 (2003), 84–90.
52. 52 Hoiby, N., Frederiksen, B., Pressler, T., Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 4:Suppl 2 (2005), 49–54.
53. 53 Ooi, C.Y., Castellani, C., Keenan, K., Avolio, J., Volpi, S., Boland, M., et al. Inconclusive diagnosis of cystic fibrosis after newborn screening. Pediatrics 135 (2015), e1377–85.
54. 54 Ren, C.L., Fink, A.K., Petren, K., Borowitz, D.S., McColley, S.A., Sanders, D.B., et al. Outcomes of infants with indeterminate diagnosis detected by cystic fibrosis newborn screening. Pediatrics 135 (2015), e1386–92.
55. 55 Groves, T., Robinson, P., Wiley, V., Fitzgerald, D.A., Long-term outcomes of children with intermediate sweat chloride values in infancy. J Pediatr 166 (2015), 1469–1474 e1-3.
56. 56 Ren, C.L., Desai, H., Platt, M., Dixon, M., Clinical outcomes in infants with cystic fibrosis transmembrane conductance regulator (CFTR) related metabolic syndrome. Pediatr Pulmonol 46 (2011), 1079–1084.
57. 57 Castellani, C., Southern, K.W., Brownlee, K., Dankert Roelse, J., Duff, A., Farrell, M., et al. European best practice guidelines for cystic fibrosis neonatal screening. J Cystic Fibros 8 (2009), 153–173.
58. 58 Cipolli, M., Castellani, C., Wilcken, B., Massie, J., McKay, K., Gruca, M., et al. Pancreatic phenotype in infants with cystic fibrosis identified by mutation screening. Arch Dis Child 92 (2007), 842–846.
59. 59 Ooi, C.Y., Dupuis, A., Ellis, L., Jarvi, K., Martin, S., Ray, P.N., et al. Does extensive genotyping and nasal potential difference testing clarify the diagnosis of cystic fibrosis among patients with single-organ manifestations of cystic fibrosis?. Thorax 69 (2014), 254–260.
60. 60 Ooi, C.Y., Dupuis, A., Ellis, L., Jarvi, K., Martin, S., Gonska, T., et al. Comparing the American and European diagnostic guidelines for cystic fibrosis: same disease, different language?. Thorax 67 (2012), 618–624.